Neuroplasticity, neurotransmitters and new directions for treatment of anomia in Alzheimer disease.

Background:Anomia is often one of the earliest signs of Alzheimer disease (AD), and progressive language impairment remains a major source of disability throughout the disease course. Aims:This article reviews the potential uses of pharmacological adjuvants to augment neuroplasticity during speech a...

Descripción completa

Detalles Bibliográficos
Publicado en:Aphasiology Vol. 28; no. 2; pp. 219 - 236
Autores principales: Falchook, Adam D., Heilman, Kenneth M., Finney, Glen R., Gonzalez-Rothi, Leslie J., Nadeau, Stephen E.
Formato: review Journal Article
Publicado: Taylor & Francis Ltd Feb2014
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104125382&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104125382
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02687038
        B6J
      jtl: Aphasiology
      issn: 02687038
      maglogo: N
    pubinfo:
      dt: Feb2014
      vid: 28
      iid: 2
      pid: 377
      pub: Taylor & Francis Ltd
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        104125382
        92942555
        92942555
        10.1080/02687038.2013.793283
        104125382
      ppf: 219
      ppct: 17
      formats:
      tig:
        atl: Neuroplasticity, neurotransmitters and new directions for treatment of anomia in Alzheimer disease.
      aug:
        au:
          Falchook, Adam D.
          Heilman, Kenneth M.
          Finney, Glen R.
          Gonzalez-Rothi, Leslie J.
          Nadeau, Stephen E.
        affil: Malcom Randall Veterans Affairs Medical Center, Gainesville, FL, USA; Department of Neurology and Center for Neuropsychological Studies, University of Florida, Gainesville, FL, USA
      sug:
        subj:
          Alzheimer's Disease Complications
          Anomia Drug Therapy
          Neuronal Plasticity
          Neurotransmitters
          Speech Therapy
          Combined Modality Therapy
          Alzheimer's Disease Physiopathology
          Enzyme Inhibitors
          Memantine
          Catecholamines
          Amphetamines
          Levodopa
          Bromocriptine
      ab: Background:Anomia is often one of the earliest signs of Alzheimer disease (AD), and progressive language impairment remains a major source of disability throughout the disease course. Aims:This article reviews the potential uses of pharmacological adjuvants to augment neuroplasticity during speech and language therapy. Main Contribution:We begin with a discussion of the nature of anomia in AD from the perspective of classical aphasia models and in terms of a parallel distributed processing model of language. Physiological functions of acetylcholine, norepinephrine and dopamine are reviewed. We consider how pharmacological manipulation of these neurotransmitters in combination with speech and language therapy has the potential to promote maintenance and restoration of the functional connectivity within the lexical, semantic and phonological networks that are the basis of propositional language. Conclusions:AD is a disease of synaptic loss. People with AD are able to reacquire knowledge, and pharmacological modulation of acetylcholine, norepinephrine and dopamine can influence the maintenance and reformation of neuronal networks.
      pubtype: Academic Journal
      doctype:
        review
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N